Close Menu

NEW YORK (GenomeWeb) – Biocept said yesterday that it has closed a previously announced $10 million public offering.

The company sold 9.1 million shares of its common stock, as well as warrants to purchase up to 9.1 million shares at a combined offering price of $1.10 per share.

Underwriters also partially exercised an over-allotment, purchasing warrants for up to 627,131 additional shares of common stock at $0.0009 per warrant. These warrants are exercisable immediately at a price of $1.10 per share and will expire five years from the date of issuance, the company said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

In PLOS this week: preconception carrier screening program results, comparative genomics-based analysis of Elizabethkingia meningoseptica, and more.

Canadian regulators are beginning to share information from new drug studies, Undark reports.

In a column at the Dallas Morning News, the Stanley Medical Research Institute's E. Fuller Torrey says the Human Genome Project hasn't delivered on promised results.

Researchers explore a possible genetic cause for some cases of sudden infant death syndrome, KOMO News reports.